Holmium Laser Urethrotomy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Holmium laser core-through urethrotomy (HoLCTU) is an endoscopic procedure using the holmium:yttrium-aluminium-garnet (Ho:YAG) laser to incise and ablate urethral strictures — areas of scar tissue (spongiofibrosis) narrowing the urethra and impairing urine flow. It is a refined form of direct vision internal urethrotomy (DVIU) in which the precision and haemostatic properties of the holmium laser replace the cold knife or electrocautery of traditional urethrotomy. The holmium laser operates at a wavelength of 2140 nm with a tissue penetration depth of 0.4 mm, producing highly localised thermal ablation of fibrous stricture tissue with minimal injury to surrounding urethral mucosa and underlying spongiosum. This limited thermal spread is theoretically advantageous in reducing secondary scarring compared to electrocautery urethrotomy, though clinical long-term recurrence rates are broadly similar for both techniques. The procedure is performed by urologists and is typically offered as the initial minimally invasive management of a first-presentation short bulbar urethral stricture (<1 cm), or in patients who are poor candidates for urethroplasty. It is performed through a cystoscope or flexible ureteroscope in a standard operating theatre urological setting.

This treatment represents an important component of modern medical management, supported by clinical evidence from multiple randomised controlled trials and systematic reviews. Treatment protocols are continually refined based on emerging evidence to optimise patient outcomes while minimising treatment burden.

Patient suitability is assessed through a structured multidisciplinary evaluation incorporating clinical history, physical examination findings, and results of relevant investigations. Treatment planning considers the full clinical context including disease characteristics, patient comorbidities, functional status, and individual treatment goals to ensure the most appropriate therapeutic approach is selected for each patient.

Holmium laser urethrotomy is indicated for symptomatic urethral stricture disease causing poor urinary stream (Qmax <10 ml/sec on free flow rate), urinary retention, recurrent urinary tract infections, or upper tract changes from obstructed voiding. Patient selection is critically important for optimising outcomes. The procedure has the best success rates for: short (<1 cm) bulbar urethral strictures on first presentation; strictures with minimal or no spongiofibrosis on urethrogram; and patients unsuitable for or declining urethroplasty due to anaesthetic risk, frailty, or personal preference. The European Association of Urology (EAU) and British Association of Urological Surgeons (BAUS) guidelines note that urethroplasty (open surgical reconstruction) achieves significantly superior long-term success rates (>85% at 5 years vs. ~40–50% for DVIU/laser at 2 years) for most stricture types and should be preferred for: strictures longer than 2 cm; any recurrence after initial urethrotomy; obliterative or near-obliterative strictures; penile urethral strictures; and strictures from lichen sclerosus or radiation. The cause of stricture (trauma, gonococcal urethritis, catheterisation, pelvic radiation, lichen sclerosus) influences technique choice, as some aetiologies carry very high recurrence rates after urethrotomy.

The procedure is performed under general or spinal anaesthesia. The patient is positioned in lithotomy. A rigid or semi-rigid cystoscope or ureteroscope is lubricated and advanced along the urethra under direct vision to the proximal limit of the stricture. If the stricture lumen is small but patent, a 0.032-inch guidewire is advanced through the stricture lumen under direct vision and fluoroscopic confirmation, providing a safety track. A 200 or 365 micron holmium laser fibre is introduced through the working channel alongside the wire. The stricture is incised at the 12 o'clock (dorsal) position — the standard incision site for bulbar urethral strictures that minimises injury to the overlying spongiosum and preserves erectile neurovascular structures. The laser vaporises scar tissue in a stepwise fashion, creating a longitudinal incision through the full thickness of the stricture until normal, pliable urethral mucosa is encountered at each end. For complete (obliterative) strictures without a visible lumen, a retrograde urethrogram and antegrade suprapubic approach may be required for a combined core-through procedure using the laser to establish a new channel. A 16–18 French silicone urethral catheter is placed post-operatively and removed at 5–7 days. The entire procedure takes 30–60 minutes.

The procedure is performed in an appropriately equipped facility by experienced specialist clinicians. Prior to commencement, the patient undergoes pre-procedural assessment including vital signs measurement, review of relevant investigations, and confirmation of informed consent. Intravenous access is established and monitoring equipment including ECG, pulse oximetry, and blood pressure monitoring is applied.

The procedural site is prepared according to aseptic technique standards. Anaesthesia or analgesia is administered as appropriate for the specific procedure and patient needs, ranging from local anaesthesia for minor procedures to regional or general anaesthesia for more complex interventions.

The procedure is performed under direct visualisation or image guidance as appropriate. Key technical steps are executed with attention to anatomical landmarks and patient safety parameters. Haemostasis is achieved and confirmed before completion. Post-procedural assessment includes clinical evaluation of the immediate result, complication surveillance, and documentation of the procedure.

Recovery room monitoring continues until the patient meets defined discharge criteria. Written post-procedural instructions covering activity restrictions, wound care, medication management, and symptoms requiring urgent review are provided before discharge.

Holmium laser urethrotomy achieves immediate improvement in urinary flow rate (Qmax) in over 85% of treated patients, with most experiencing dramatically better voiding immediately after catheter removal. The procedure's primary advantages over open urethroplasty are: no external incision, shorter operative time (30–60 minutes vs. 2–4 hours), no perineal or scrotal wound to heal, same-day or next-day discharge, and faster recovery. This makes it an attractive first-line option for medically frail patients or those preferring to avoid open surgery initially. For first-presentation short (<1 cm) bulbar strictures, the published success rate is approximately 50% at 5 years — meaning half of patients remain free of symptomatic recurrence without further intervention. The holmium laser's superior haemostasis compared to cold knife DVIU allows better intraoperative visibility and may be advantageous for vascular stricture areas. The procedure can be repeated if recurrence occurs, providing multiple opportunities for minimally invasive management before urethroplasty is considered. Intermittent urethral self-dilation (clean intermittent catheterisation with a 14–16 French catheter, 2–3 times weekly) after urethrotomy has been shown in randomised trials to improve 12-month success rates from 40% to 70% in short bulbar strictures.

The primary limitation and risk of holmium laser urethrotomy is stricture recurrence, which occurs in 50–60% of patients within 2 years for most stricture types. Recurrence rates are highest for: longer strictures (>2 cm), strictures with dense spongiofibrosis, penile and peno-bulbar location, previous failed urethrotomy, and radiation or lichen sclerosus aetiology. Urinary tract infection post-procedure occurs in 5–10% and is managed with oral antibiotics; prophylactic antibiotics are routinely given. Haematuria for 24–48 hours after catheter removal is expected and self-limiting. Extravasation of irrigant from laser perforation of the urethral wall may cause transient perineal or scrotal swelling and is managed conservatively with extended catheterisation. Erectile dysfunction has been reported in less than 2% of patients after bulbar urethrotomy and is attributed to thermal injury to surrounding corpus spongiosum; the holmium laser's limited penetration depth is theoretically less harmful than electrocautery in this regard. Retrograde ejaculation from the incision through the distal sphincter can occur when urethrotomy extends beyond the bulbar into the membranous urethra. Urethral false passage from blind instrumentation during the procedure is avoided by maintaining guidewire track access.

Most patients are discharged the same day or the morning after the procedure with a urethral catheter in place. The catheter remains for 5–7 days following standard urethrotomy; some centres advocate 3 days for very short strictures. Upon catheter removal, patients void spontaneously and flow rates are measured at 6–8 weeks to document improvement and detect early recurrence. A short course of oral antibiotics (trimethoprim or cefalexin) is prescribed during catheterisation. Post-procedure urinary burning and increased frequency for 3–5 days after catheter removal are normal and resolve spontaneously. Adequate hydration (2 litres daily) reduces urinary symptoms and infection risk. Driving and desk work may resume the day after catheter removal; strenuous physical activity should be avoided for 1 week. Sexual activity may resume after catheter removal once comfortable. Follow-up with free flow rate measurement is arranged at 6 weeks; surveillance urethrography or flexible urethroscopy may be arranged at 3–6 months in high-risk cases. Patients counselled on intermittent self-dilation post-urethrotomy should be provided with a catheter size and schedule to begin in the week following catheter removal.